Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.21
- Piotroski Score 1.00
- Grade Buy
- Symbol (SAVA)
- Company Cassava Sciences, Inc.
- Price $25.50
- Changes Percentage (1.27%)
- Change $0.32
- Day Low $25.40
- Day High $26.58
- Year High $42.20
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
- Last Earnings 12/08/2012
- Ex-Dividend for 5/16 Dividend 12/13/2012
- Dividend Payable 12/24/2012
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.17
- Trailing P/E Ratio -9.05
- Forward P/E Ratio -9.05
- P/E Growth -9.05
- Net Income $-97,217,000
Income Statement
Quarterly
Annual
Latest News of SAVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate
Savara's downgrade by Evercore ISI to "in line" from "outperform" is due to concerns over Molbreevi's FDA approval. Issues with manufacturing capacity and partners raise doubts about the medication's ...
By Yahoo! Finance | 21 hours ago -
Savannah Guthrie's Daughter Vale, 10, Is Her Biggest Supporter as She Leaves Mom a Sweet Note on Election Day: 'You Got This'
Hannah Sacks, a Parents team writer/reporter at PEOPLE since May 2023, has contributed to various publications. Savannah Guthrie shared a sweet note from her daughter Vale on Election Day, expressing ...
By PEOPLE.com | 1 week ago -
'Jeopardy!' host Ken Jennings takes savage dig at rival Ryan Seacrest...
During a recent "Jeopardy" taping, host Ken Jennings joked about rival "Wheel of Fortune" host Ryan Seacrest, lightening the rivalry. Jennings' humility and kindness on set have been well-received....
By New York Post | 1 week ago
